Literature DB >> 13701377

Mitomycin C (NSC-26980)--an evaluation of the Japanese reports.

W FRANK, A E OSTERBERG.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/therapy

Mesh：

Substances：

Year:  1960        PMID： 13701377

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  10 in total

1.  Mitomycin C: experience in the United States, with emphasis on gastric cancer.

Authors:  P S Schein; J S Macdonald; D Hoth; P V Wooley
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.

Authors:  R G Buice; H B Niell; P Sidhu; B J Gurley
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 3.  Progress report. Cytotoxic therapy for gastrointestinal carcinoma.

Authors:  T J Prostman
Journal:  Gut       Date:  1976-04       Impact factor: 23.059

Review 4.  Alkylating anticancer agents and their relations to microRNAs.

Authors:  Bernhard Biersack
Journal:  Cancer Drug Resist       Date:  2019-03-19

Review 5.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the stomach and carcinoid tumors.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-07       Impact factor: 1.798

6.  Bronchial artery infusion of mitomycin C in carcinoma of the lung.

Authors:  S Ekholm; U Albrechtsson; U Tylén
Journal:  Cardiovasc Intervent Radiol       Date:  1983       Impact factor: 2.740

7.  In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines.

Authors:  A Ghiorghis; A Talebian; R Clarke
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Update in cancer chemotherapy: gastrointestinal cancer--colorectal cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-04       Impact factor: 1.798

9.  Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).

Authors:  S K Shipp; H B Muss; M A Westrick; M R Cooper; D V Jackson; F C Richards; D R White; J J Stuart; R M Christian; W Ramseur
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Pharmacokinetics of mitomycin C in rabbit and human.

Authors:  G A van Hazel; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.